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Letter to the Editor 
 
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of clonal B-
cells in peripheral blood and lymphoid tissues 1. Circulating CLL cells are non-dividing B 
lymphocytes, but a significant fraction of the clone proliferates in lymphoid tissues where 
they receive a plethora of signals from the microenvironment that promote their survival 
and expansion 2. Cathelicidins are a family of proteins with antibacterial functions mainly 
expressed by neutrophils, macrophages and epithelial cells 3. In humans, the only member 
of this family, hCAP18, is encoded by the gene CAMP. The cleavage of hCAP18 generates 
the antimicrobial peptide LL-37, which has been recently implicated in the promotion of 
tumor growth, through direct stimulation of malignant cells, initiation of angiogenesis and 
recruitment of immune cells 4. In this study, we investigated the role of hCAP18/LL-37 in 
CLL.  
Clinical features of analyzed patients are shown in Supplementary Table 1. By gene 
expression analysis, we found that CAMP is up-regulated in CLL cells compared to B cells 
from age-matched healthy donors (HD) (Supplementary Figure 1), and this was confirmed 
by qRT-PCR (Figure 1a). Interestingly, when samples were discriminated according to 
their IGHV mutation status, those with unmutated IGHV (poor clinical outcome, U-CLL) 
showed significantly higher levels than those with mutated IGHV (better outcome, M-
CLL). Similarly, leukemic cells from patients in Rai III/IV stages expressed higher levels 
of hCAP18 mRNA compared to indolent Rai 0 patients (Figure 1b), suggesting that 
transcription of CAMP is related to an aggressive clinical phenotype. Nevertheless, flow 
cytometry analysis, using polymorphonuclear cells (PMNs) as a positive control, did not 
reveal hCAP-18/LL-37 protein expression in circulating CLL cells or B lymphocytes from 
healthy donors (Supplementary Figure 2).  
Given that CLL cells in lymphoid tissues possess a distinct phenotype, with enhanced 
expression of anti-apoptotic and activation markers compared to circulating cells 5, we 
looked for hCAP18/LL-37 in bone marrow biopsies. Figure 1c shows that a proportion of 
leukemic cells (CD20+) and almost all myeloid cells (CD68+) cells expressed hCAP18/LL-
37. These results suggest that signals from the microenvironment promote the expression of 
hCAP-18/LL-37 protein in CLL cells. To assess this possibility we stimulated circulating 
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CLL cells with different well-known stimuli, such as CD40L, CpG, immobilized anti-IgM, 
IL-4 and IL-15. Results show that these stimuli up-regulated the transcription of CAMP 
(Figure 1d) and, more importantly, those stimuli that were most effective in increasing 
hCAP18 mRNA, i.e. CpG+IL15 and CD40L+IL4, induce the expression of hCAP18/LL-37 
protein (Figure 1e). We also observed a significant though moderate correlation between 
mRNA and protein levels of hCAP18/LL-37 after cellular activation (Supplementary 
Figure 3). Compared to neutrophils, the intracellular expression of hCAP18/LL-37 in 
activated CLL was modest. However it should be taken into account that hCAP18/LL-37 is 
stored in neutrophils granules at very high concentrations (0.6 µg per 106 cells)6, while it 
appears to be released to supernatant by activated CLL cells (Figure 1f).  
hCAP18/LL-37 has been shown to participate as a tumor promoting factor in breast and 
lung cancers and in pancreatic ductal adenocarcinoma 4,7. In those settings, hCAP18/LL-37 
acts mainly as a growth factor inducing tumor cell activation, survival and proliferation. 
Since CLL cells proliferate minimally in vitro, even upon strong stimulation, we assessed if 
LL-37 could induce leukemic cell activation and inhibit spontaneous and drug-induced 
apoptosis. We found that incubation of CLL cells with LL-37 at 5 or 10 µM did not 
increase the expression of activation markers (not shown), but significantly delayed 
spontaneous apoptosis of leukemic cells as evaluated by binding of Annexin V (Figure 2a-
b). These concentrations are found at sites of inflammation, like bronchoalveolar lavage 
fluid from infants with pulmonary infections 8 or psoriatic skin lesions 9. Of note, LL-37 
not only inhibited spontaneous CLL apoptosis but also interfered with that induced by 
ABT-199 or fludarabine, agents currently employed for CLL treatment 1 (Figure 2c-d and 
Supplementary Figures 4 and 5). In addition to AnnexinV staining, inhibition of apoptosis 
by LL-37 was corroborated analyzing caspase 3 cleavage (Figure 2.e) and BCL-2 
expression (Supplementary Figure 5b). Because delay of neutrophil apoptosis by LL-37 has 
been reported to depend on two different receptors: FPRL1 and P2X7 10, we tested if 
WRW4 (FPRL1 antagonist) or KN-62 (P2X7 inhibitor) could counteract the protective 
effect of LL-37. Figure 3a shows that none of these agents interfered with LL-37 activity 
indicating that neither FPRL1 nor P2X7 were involved. 
LL-37 can also interact with CXCR4 11, the receptor for the chemokine CXCL12, 
which plays an important role in CLL by promoting the migration of leukemic cells to 
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lymphoid tissues and improving their survival 12. Therefore, we determined if CXCR4 was 
involved in the anti-apoptotic pathway triggered by LL-37. We found that an antibody 
directed to CXCR4 that blocks CXCL12 engagement impaired LL-37 protection (Figure 
3b). Furthermore, confocal microscopy shows co-localization of LL-37 and CXCR4 on the 
cell membrane indicating that both molecules are in the same patches on CLL surface 
(Figure 3c). Finally, we evaluated CXCR4 endocytosis since this is a mandatory step for 
chemokine receptors upon binding cognate chemokine, in this case CXCL12. The 
interaction of CXCR4 with LL-37 at 37ºC led to downregulation of CXCR4 from the CLL 
cell surface (Figure 3d). Altogether, these results suggest that CXCR4 could be acting as a 
LL-37 receptor on CLL cells.  
Since it was previously reported that LL-37 enhances the chemotactic responsiveness of 
hematopoietic progenitors to low doses of CXCL12 11, we evaluated if this was also true 
for CLL cells. To address this, we used transwell chambers and assessed leukemic cell 
migration towards a suboptimal concentration of CXCL12 (25 ng/ml), with or without LL-
37 (5 µM). As was the case for hematopoietic progenitors, LL-37 increased the migratory 
response of CLL cells to CXCL12. Of note, LL-37 did not induce chemotaxis of CLL cells 
by itself, as demonstrated in neutrophils acting through FPRL110 and in keratinocytes 
through transactivation of the epidermal growth factor receptor 13 (Figure 3e).  
Accumulating evidence supports pro- or anti-tumorigenic roles for hCAP18/LL-37 in 
various types of human cancer, e.g., pro-tumor in ovarian, lung and breast cancer and in 
malignant melanoma, and anti-tumor in colon and gastric tumors 4. In agreement with its 
inflammatory and pro-angiogenic activity, hCAP-18/LL-37 expression in most solid tumors 
correlates with increased leukocyte infiltration and microvessel density. In breast and lung 
cancers, exogenous LL-37 promotes cell proliferation and metastasis 4, but it induces 
G0/G1 cell cycle arrest in gastric cancer cells, suggesting that the effect of hCAP18/LL-37 
depends on the tissue origin of the tumor. Moreover, it is important to consider that 
hCAP18/LL-37 can also be expressed by stromal and myeloid cells in the 
microenvironment. In fact, malignant cells are able to promote the expression of 
hCAP18/LL-37 by tumor associated macrophages as occurs in pancreatic ductal 
adenocarcinomas where the secreted peptide contributes to tumor progression 7. Similarly, 
6 
 
in a murine model of prostatic cancer, overexpression of CAMP in tumor cells favors the 
differentiation of early myeloid progenitors into protumorigenic M2 macrophages 14. 
Here we show that, unlike normal B lymphocytes, leukemic B cells from CLL patients 
express hCAP18 mRNA and that this expression associates with poor prognosis and 
disease stage. Interestingly, we found that circulating CLL cells can produce and release 
hCAP18/LL-37 protein upon in vitro activation with microenvironmental stimuli and this 
observation was supported by bone marrow immunohistochemistry. In vitro, exogenous 
LL-37 delays CLL cell apoptosis, both spontaneous and that induced by chemotherapeutic 
agents. As an antimicrobial peptide, the main function of LL-37 is to induce bacterial lysis 
via the formation of transmembrane pores 15. Cellular membranes associated with 
cholesterol, such as those from human cells, are resistant to LL-37 toxicity unless 
supraphysiological concentrations are used. By contrast, LL-37 has antiapoptotic effects in 
a variety of cells including neutrophils through FPRL1 and P2X7 10. We have shown that 
these two receptors are not involved in CLL cell protection by LL-37, but rather this 
depends on CXCR4, a key receptor for CLL cell survival and traffic. Of note, LL-37 was 
able to enhance leukemic cell migration towards suboptimal concentrations of CXCL12.  
In conclusion, our results suggest that hCAP18/LL-37 may have an active role in the 
CLL-tumor microenvironment by increasing leukemic clone retention and survival in 
lymphoid tissues. 
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Legends to Figures: 
Figure 1.  hCAP18/LL-37 expression in CLL cells. 
A.Left panel: hCAP18 mRNA expression was evaluated in purified B-cells from healthy 
donors (HD) (n=7) and CLL cells (n=41) samples by qRT-PCR. Results were normalized 
to β-actin human gene and are represented as relative units (2-Δct×103). Statistical analysis 
was performed using Mann-Whitney test. Shown are individual values and mean ± SEM. 
Right panel: hCAP18 mRNA expression on CLL cell samples discriminated based on their 
IgVH mutational status. Unmutated (U-CLL) n= 21, Mutated (M-CLL) n=20. B. The 
average expression of mRNA hCAP18 in CLL cell samples was calculated and patients 
were separated into 2 groups: those with hCAP18 levels below the average (low-hCAP18) 
and those with hCAP18 levels above the average (high-hCAP18). Chi-square test showed a 
statistically significant association between hCAP18 expression and CLL clinical stage (Rai 
staging). C. Expression of hCAP18/LL-37 on bone marrow biopsies from CLL patients. 
8 
 
Samples were doubled-stained to identify LL-37 in myeloid cells (CD68+) and CLL cells 
(CD20+) as detailed in the supplementary Materials and Methods. Shown are representative 
pictures for H/E staining, hCAP18 single staining and CD68+ or CD20+/hCAP18 double 
staining, n=5 (left panel). Image magnification: 600x. Arrow heads represent hCAP18 
single positive cells (a) or double positive (CD20/hCAP18) cells (b). At the right  panel, pie 
charts displaying the total percentage of hCAP18 positive cells and the contribution of each 
cell type (CD68+,CD20+ and others) are shown  D.hCAP18 mRNA expression in CLL cells 
stimulated with CpG (5µg/ml), CpG + IL-15 (10ng/ml), immobilized anti-IgM Ab 
(0.1µg/ml), anti-IgM Ab + IL-4 (15ng/ml), anti-IgM Ab + CD40L (500ng/ml), CD40L or 
CD40L + IL-4 for 48 hours at 37ºC. Results are expressed as fold increase compared to 
control (unstimulated condition). Statistical analysis was performed using Friedman test 
and Dunn’s multiple comparison test. Shown are individual values and mean ± SEM. Blue 
dots correspond to M-CLL and red dots to U-CLL samples. Asterisks represent p<0.05. E. 
Intracellular expression of hCAP18/LL-37 in CLL cells activated with CpG + IL-15 or 
CD40L + IL-4 for 48 hours at 37ºC. Results are expressed as the ratio of median 
fluorescence intensity (MFI) of hCAP18/LL-37 to MFI of isotype control in CD19+ cells 
(blue dots: M-CLL, red dots: U-CLL) or in PMNs (positive control). Individual values and 
mean ± SEM are shown. F. LL-37 concentration in culture supernatants of activated CLL-
cells quantified by ELISA. Statistical analysis was performed using Friedman test and 
Dunn’s multiple comparison test (p<0.05). Shown are individual values and mean ± SEM. 
(blue dots: M-CLL, red dots:U-CLL). 
Figure 2.  LL-37 inhibits spontaneous and ABT-199 induced apoptosis of CLL cells. 
Peripheral blood mononuclear cells (PBMC) samples from CLL patients were incubated 
with LL-37 (2.5-10 μM) for 48 hours 37ºC. Cells were stained with PC5-anti-CD19 mAb 
and AnnexinV-FITC and analyzed by flow cytometry. (A) Shown are representative CD19 
vs AnnexinV dot plots (blue dots: M-CLL, red dots:U-CLL) and the percentage of 
apoptotic cells (mean ± SEM, n=12). (B) PBMC samples from CLL patients were 
incubated with ABT-199 (0.01 μM) with or without LL-37 (5 μM) for 48 hours at 37ºC. C-
D. Apoptosis was assessed by flow cytometry as described in (A). Depicted are 
representative CD19 vs AnnexinV dot plots and the percentage of apoptotic cells (mean ± 
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SEM, n=13). Statistical analysis was performed using Friedman test and Dunn’s multiple 
comparison test (p<0.05). E. Leukemic cells were treated with ABT-199 (0.1µM) for 18 h 
with or without LL-37 (5 µM). The activation of the apoptotic program was analyzed by 
caspase-3 cleavage and flow cytometry. Shown are representative histograms (n=5). 
Figure 3.  Role of CXCR4 in LL-37 effects on CLL cells: 
PBMCs from CLL patients were incubated with WRW4 (1 μM), KN-62 (1 μM) or both for 
30 min before adding LL-37 (5 μM). Cells were cultured for 48 hours at 37ºC and apoptosis 
was evaluated as described in Figure 2. A. The percentages of apoptotic CLL cells are 
shown (mean ± SEM, n= 5). Statistical analysis was performed using Friedman test and 
Dunn’s multiple comparison test (p<0.05). B. PBMCs from CLL patients were incubated 
with anti-CXCR4 Ab (10 μg/ml) for 30 min before adding LL-37 5μM. Cells were cultured 
for 48 hours at 37ºC. A fresh aliquot of anti-CXCR4 was re-added at 24 hours. Apoptosis 
was evaluated at 24 and 48 hours as described in Figure 2. Shown are the percentages of 
apoptotic cells (mean ± SEM, n=6). Statistical analysis was performed using Friedman test 
and Dunn’s multiple comparison test (p<0.05). C. CLL cells were incubated for 30 min 
with LL-37 (5 µM), then fixed with 4% paraformaldehyde and labeled with rabbit anti-LL-
37 IgG followed by Dy-Light 488-anti-rabbit IgG (green) and anti-CXCR4-PE IgG (red). 
Colocalization areas are indicated by the arrowheads. The bar indicates 15μm. D. Time-
dependent downregulation of CXCR4 on CLL cells induced by LL-37. CLL cells were 
incubated with LL-37 (5µM) at 37ºC for the indicated time and the expression of 
membrane CXCR4 was evaluated by flow cytometry. Results are expressed as MFI (mean 
± SEM, n=5). Statistical analysis was performed using Friedman test and Dunn’s multiple 
comparison test (p<0.05). E. LL-37 enhances the migration of LLC cells towards CXCL12. 
CLL cells (2x106 cells/ml) were seeded in the upper chamber of transwell plates to evaluate 
their migration to the lower compartment in response to CXCL12 (25 ng/ml) in the 
presence or absence of LL-37 (5 μM). Cells were incubated for 120 min, recovered from 
the lower chamber and quantified by flow cytometry. The migration index was calculated 
as the subtraction of the number of CD19+ cells that migrated spontaneously (control 
without chemokine) from the number of CD19+ cells that migrated in the presence of 
CXCL12 and normalized to the input .Shown are mean ± SEM (n = 7). Statistical analysis 
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was performed using Friedman test and Dunn’s multiple comparison test (p<0.05). In all 









SUPPLEMENTARY MATERIALS AND METHODS 
 
Reagents and antibodies. 
 
RPMI 1640, fetal calf serum (FCS), penicillin, trypsin and streptomycin were purchased 
from GIBCO. The Ficoll-Hypaque Plus used for cell separation was purchased from 
Amersham. MACS B and B-CLL cell isolation kits were purchased from Miltenyi 
Biotec. Bovine serum albumin (BSA) used for cell staining buffer was obtained from 
Weiner Laboratorios. Dimethyl sulfoxide (DMSO) was purchased from Sigma-Aldrich. 
Venetoclax (ABT-199) and fludarabine phosphate were purchased from MedKoo 
Biosciences, Inc. Annexin-V FITC and propidium iodide (PI) were purchased from BD 
Bioscience, Pharmingen. Purified anti-CD3 (clone UCHT1) and PC5 conjugated mAb 
specific for CD19 (clone J3-119) were obtained from Beckman Coulter. Two different 
anti- Hcap18/LL-37 antibodies were used: purified anti-CAP 18 (mouse mAb, clone H7) 
from BioLegend and purified anti-LL-37 (rabbit polyclonal IgG) from Santa Cruz 
Biotechnology. Mouse anti-LL-37 mAb was conjugated with PerCP-Cy5.5 using 
Lightning-link PerCP-Cy 5.5 Tandem Conjugation kit from Innova Biosciences. Purified 
anti-CXCR4 (mouse mAb, clone 12G5), PE-conjugated anti-CXCR4 (clone 12G5), anti- 
CD20 (mouse mAb, clone 2H7) and antibodies with irrelevant specificities (isotype 
control) were purchased from BioLegend. Anti-CD68 (mouse mAb, clone PGM1) was 
purchased from DAKO. Anti-human IgM (Fab´2 fragments) and all the secondary 
antibodies were obtained from Jackson ImmunoResearch. Human IL-4, IL-15 and 
CD40L were purchased from BioLegend. Human CXCL12 was purchased from 
Peprotech. CpG- ODN 2006 and the synthetic LL-37 peptide were purchased from 
Invivogen. Human LL-37 ELISA kit was purchased from Hycult Biotech. WRW4 was 
from Phoenix Pharmaceuticals. Aqua-Poly/Mount coverslipping medium was purchased 
from Polysciences (Warrington, PA, USA). Red alkaline phosphatase (Red AP) substrate 
kit and DAB peroxidase substrate kit were purchased from Vector Laboratories. Unless 
otherwise stated, all the chemicals employed were from SIGMA-Aldrich. Cleaved 




CLL patients and age-matched healthy donors. 
 
This study included 55 CLL patients and 6 age-matched healthy donors (HD). Peripheral 
blood samples were collected from CLL patients and HD. Bone marrow biopsies were 
obtained from 5 CLL patients. All samples used in this study were obtained after 
informed consent in accordance with the Declaration of Helsinki and with Institutional 
Review Board approval from the National Academy of Medicine, Buenos Aires, 
Argentina and the Institutional Review Board of Northwell Health, New York, US. CLL 
was diagnosed according to standard clinical and laboratory criteria. At the time of 
analysis, all patients were free from clinically relevant infectious complications and 
either had received no treatment or had not received treatment for ≥3 months before the 
investigation began. Peripheral blood mononuclear cells (PBMC) from CLL patients and 
healthy donors (HD) were separated by density gradient centrifugation (Ficoll, GE 
Healthcare), frozen (10% DMSO, 45% FBS, and 45% RPMI), and stored in liquid 
nitrogen until used. 
Total RNA preparation, cDNA synthesis and qRT-PCR. 
 
Total RNA was extracted from 2 x 10
6
 purified B cell from HD-PBMC or 3 x10
6
 CLL 
PBMCs (monocyte depleted samples with more than 98% of leukemic cells) using 
Qiagen RNeasy mini kit and cDNA was generated by reverse transcription with 
SuperScript II according to the manufacturer´s instructions. qRT-PCR was performed 
using SYBR Green PCR Master Mix in 20 µl reactions. Primers were designed using 
Primer3 software and purchased from Thermo-Fisher Scientifics: β-ACTIN Fw 5´-GAG 
CGC GGC TAC AGC TTC AC- 3´, β-ACTIN Rv 5´- GTG TAA CGC AAC TAA GTC 
AT -3´,hCAP18 Fw 5´- GATAACAAGAGATTTGCCCTGCTG-3´, hCAP18 Rv 5´-
TTTCTCAGAGCCCAGAA 
GCCTG-3´, and were used at a concentration of 250 nM. Reactions were carried out in 
an Applied Biosystems (ABI) 7900HT Real-Time PCR System from the PCR facility 
from The Feinstein Institute for Medical Research. The cycling program used was 50 ˚C 
for 2 minutes, 95˚C for 1 minute, followed by 40 cycles of 95˚C for 15 seconds, 60˚C for 




 CLL cells activation in vitro. 
 
 CLL cells (2 x 10
6
 cells/ml) were cultured in 24 well plate in RPMI 1640 + 10% FCS alone 
(control) or in the presence of immobilized anti-IgM (0.1 µg/ml), CD40L (500 ng/ml), CpG 
(5 μg/ml), IL-15 (10ng/ml) or IL-4 (15ng/ml) alone or in different combinations depicted in 
Fig 1.e. After 48 hours of culture, CLL cells were collected, and activation was confirmed 
by flow cytometry by evaluating the surface expression of CD69/CD25/CD86 using mAbs 
anti-CD69-PE, anti-CD86-PE and anti-CD25-FITC or the corresponding isotype control 
and anti-CD19-PC5. Quantification of mRNA on control and activated CLL-cells was 
assessed by qRT-PCR, as described above as well as intracellular hCAP18/LL-37 staining 
using an anti-LL-37- PerCP-Cy5.5. Supernatants of CLL-cultures were collected and the 
presence of soluble LL-37 was assessed by ELISA. 
Bone marrow immunohistochemistry. 
 
Bone marrow biopsies from CLL-patients were stained to assess the presence of 
hCAP18/LL-37. Samples were doubled-stained in order to determine which cells express 
LL-37. Staining of LL-37/CD68 and LL-37/CD20 were performed. LL-37 expression was 
confirmed using Vector Red (Vector Lab) substrate for alkaline phospathase (Red 
precipitate) while CD68/CD20 expression were observed with DAB substrate (Vector 
Lab) for peroxidase (Brown precipitate). 
Detection of leukemic cell apoptosis. 
 
After their respective treatments, leukemic cells were incubated for 20 min with anti-
CD19 at 4°C, washed with PBS and incubated for 30 minutes with AnnexinV-FITC at 
room temperature. Once the incubation time was completed, apoptosis levels (AnnexinV
+
) 
were recorded by flow cytometry. In addition, activated caspase-3 (cleaved) was measured 
by intracellular staining. Treated CLL-cells were fixed with PFA 4% during 30 min at 
room temperature, then washed twice with PBS and permeabilized during 30 min with 
0.01% TritonX100-PBS-4% FCS (Triton buffer). After that, cells were incubated with 
anti-cleaved caspase-3 Ab for 30 min at 4ºC, washed twice with Triton buffer and 










 cells/ml) were incubated with LL37 (5μM) for 30 minutes. Then cells 
were washed once with PBS and fixed with PFA 4% for 1 hour. After fixation cells were 
blocked with 5% BSA for 45 minutes. Subsequently cells were washed and incubated 
with polyclonal rabbit anti-LL37 antibody (Biolegend) for 2 hours. Cells were then 
washed and incubated with anti-rabbit IgG antibody labeled with DyLight 488 for 2 hours. 
Then cells were washed twice and incubated with PE-conjugated anti-CXCR4 for 30 
minutes. Once the labeling protocol was completed, cells were incubated for 18 hours on 
slides previously treated with poly-L-lysine and then mounted using Aqua-Polymount. 
The images were acquired using a confocal microscope Olympus FluoView FV1000. 
Migration assays of CLL-cells in response to CXCL12/LL-37. 
 
For the chemotaxis assays, transwell plates (Corning Incorporated) of 96 wells, with 
polycarbonate membranes of 6.5 mm in diameter and pores of 5 μm were used. In the 
lower compartment, 200 μl of RPMI 1640 medium (1% SFB) was added containing 
CXCL12 (25ng / ml) with or without LL-37 (5μM) and in the upper chamber leukemic 
cells (1 x 106) were seeded. As spontaneous migration control the same assay was 
performed without adding CXCL12 in the lower compartment. Each experimental 
condition was carried out in duplicate. CLL-cells were incubated at 37 °C for 2 hours. 
After this time, the cells that migrated to the lower compartment were collected and 
labeled with anti- CD19 to identify leukemic B cells. Cell counting was performed by 
flow cytometry determining the number of cells that are acquired in a minute. The 
migration index was calculated as the number of CD19
+
 cells that migrated to the lower 
chamber with CXCL12/LL-37 compared to the number of cells that migrated 
spontaneously (control without chemokine). 
 
Patient Age Gender IgVH status  Rai stage 
CLL1 81 F M 0 
CLL2 81 M U 0 
CLL3 75 F M 0 
CLL4 58 M U I 
CLL5 59 M U 0 
CLL6 80 M M III 
CLL7 78 F M II 
CLL8 75 M M III 
CLL9 86 M U II 
CLL10 58 F U I 
CLL11 85 F U III 
CLL12 62 M M 0 
CLL13 67 M M IV 
CLL14 46 M M I 
CLL15 58 F M I 
CLL16 55 F M I 
CLL17 84 M M II 
CLL18 53 M M II 
CLL19 54 M M I 
CLL20 66 F U I 
CLL21 81 M U III 
CLL22 55 F U II 
CLL23 62 M M 0 
CLL24 59 M M I 
CLL25 79 F M I 
CLL26 71 F U I 
CLL27 58 M U I 
CLL28 88 F U IV 
CLL29 70 F U 0 
CLL30 79 F M 0 
CLL31 69 F U I 
CLL32 87 F U 0 
CLL33 76 M M I 
CLL34 54 F M I 
CLL35 39 M U 0 
CLL36 62 F U IV 
CLL37 44 M U II 
CLL38 34 F M 0 
CLL39 62 M U III 
CLL40 66 F U II 
CLL41 72 M U III 
CLL42 82 F M 0 
CLL43 67 M U II 
CLL44 74 M M 0 
CLL45 44 F U 0 
CLL46 85 M M IV 
CLL47 83 M M I 
CLL48 60 M M III 
CLL49 78 F U 0 
CLL50 77 M M I 
CLL51 74 M M 0 
CLL52 64 M U IV 
CLL53 54 F M I 
CLL54 69 M M II 
CLL55 52 F M 0 
Supplementary table 1. 
Clinical staging and IGVH mutational status of patients enrolled in the study. 
Supplementary Figure S1. 
Supplementary Figure S1. Gene profiling analysis of CAMP in CLL and HD B cells.  
RNA was purified from B cells of 26 CLL (CD5+CD19+), and 11 HD (CD5-CD19+ or 
CD5+CD19+), and gene expression was measured with Illumina HumanHT12 
beadchips. Microarray data were normalized using quantile normalization by 
GenomeStudio software (Illumina).  
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Supplementary Figure S2. hCAP18/LL-37 intracelullar staining gating strategy. 
 
PBMC from CLL patients were cultured in complete medium (panel a) or in the presence 
of CpG + IL15 (panel b) for 48 hours at 37ºC. Then, 0.5 x 106 cells were labeled with 
anti-CD19 PC5, washed and mixed with 0.5 x 106 PMN cells from a healthy donor. Cells 
were fixed with 1% PFA and permeabilized with PBS 0.05% saponin. The cell mixture 
was separated in two aliquots: one was labeled with isotype control and the other with 
anti-hCAP18/LL37 mAb. Shown are FSC-H vs SSC-H dot plots with PMN region in red 
and lymphocytes region in blue. Histograms show hCAP18 fluorescence intensity in 
PMN, resting CLL cells (a) or activated CLL cells (b).  Isotype control is depicted as 
empty histogram. Shown is a representative experiment, n=7. 
C. PBMC from healthy donors were labeled as described for cultured CLL cells. 
Shown is a representative experiment, n=3. 
Supplementary Figure S3. 
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Supplementary Figure S3. Correlation of hCAP18 mRNA and protein levels after 
CLL-cells activation.  
 
Spearman correlation analysis (p<0.05) between hCAP18 transcript and protein levels 
were performed in activated CLL-cells. Different colored dots represent IGVH mutational 
status: red (U-CLL) and blue (M-CLL). 
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Supplementary Figure S4. Effect of LL-37 on CLL cell apoptosis induced by ABT-
199 at clinically relevant concentrations.  
 
CLL cells were treated with ABT-199 (0.1 or 1μM) during 24hs with or without addition of 
LL-37 (5 μM). Apoptosis was evaluated by flow cytometry using Annexin V. Statistical 
analysis was performed using Friedman test and Dunn’s multiple comparison test 
(p<0.05). Different colored dots represent IGVH mutational status: red (U-CLL) and blue 
(M-CLL). 
Supplementary Figure S5. 
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Supplementary Figure S5. LL-37 inhibits Fludarabine-induced apoptosis of CLL 
cells.  
PBMC samples (> 95% leukemic cells) from CLL patients were exposed to Fludarabine 
(12.5 μg/m) with or without LL-37 (5 μM) for 48hs at 37ºC and apoptotic levels or BCL-2 
expression were analyzed. (a.) Representative CD19 vs AnnexinV dot plots and the 
percentage of apoptotic cells (mean ± SEM, n=7) are shown. Statistical analysis was 
performed using Friedman test and Dunn’s multiple comparison test. B. Bcl-2 western 
blot and quantification are shown (mean ± SEM, n=5). -actin was used as loading 
control. Statistical analysis was performed using Friedman test and Dunn’s multiple 
comparison test. 
a. 
b. 
